What is Gentegra?
Gentegra operates at the intersection of molecular biology and logistics, providing specialized solutions for the stabilization and protection of genetic material. The company's core product suite, including GenTegra RNAdvantage and GenTegra RNAssure, addresses the degradation risks inherent in RNA and DNA storage. By enabling room-temperature stability for sensitive samples, Gentegra eliminates the reliance on cold-chain logistics, thereby reducing operational costs and enhancing sample integrity for sequencing and diagnostic applications. Their technology is widely utilized across forensic labs and clinical research environments, ensuring that biological data remains viable from the point of collection through to final analysis.
How much funding has Gentegra raised?
Gentegra has raised a total of $108K across 1 funding round:
Debt
$108K
Debt (2021): $108K with participation from PPP
Key Investors in Gentegra
PPP
Public-Private Partnership
What's next for Gentegra?
With this major strategic investment, Gentegra is poised to accelerate its market penetration within the high-growth genomics and molecular diagnostics sectors. The capital will likely be deployed to scale manufacturing capabilities and expand the reach of their forensic DNA storage solutions. As the demand for reliable, long-term sample archiving grows in tandem with the expansion of personalized medicine, Gentegra is well-positioned to leverage its proprietary stabilization technology to capture additional market share. Future growth trajectories will likely focus on deepening partnerships with large-scale biobanks and integrating their stabilization protocols into automated high-throughput laboratory workflows.
See full Gentegra company page
